Literature DB >> 23044811

Helicobacter pylori is not the predominant etiology for liver cirrhosis patients with peptic ulcer disease.

Shen-Shong Chang1, Hsiao-Yun Hu.   

Abstract

OBJECTIVES: Patients with liver cirrhosis (LC) often develop peptic ulcers. The differentiation of Helicobacter pylori etiology in LC patients from that of peptic ulcers in non-LC patients is critical. This study aimed to determine whether H. pylori plays a central role in LC patients with peptic ulcers.
METHODS: LC was defined by International Classifications of Diseases, Revision 9, and Clinical Modification (ICD-9-CM) codes 571.2, 571.5, and 571.6. To be defined as non-LC, we did not identify patients in an inpatient setting or by one or more ambulatory care claims containing the International Classifications of Diseases, Revision 9, and Clinical Modification codes 571.2, 571.5, and 571.6. The sample included 9465 H. pylori-positive patients and 3418 H. pylori-negative patients. A logistic regression model was used to calculate the odds ratio (OR) and a 95% confidence interval was used to determine whether LC was an independent factor of lower H. pylori infection rates in peptic ulcer patients.
RESULTS: This study included 102 decompensated LC patients with peptic ulcers, 39 H. pylori-positive and 63 H. pylori-negative. There were 360 compensated LC patients with peptic ulcers, 193 H. pylori-positive and 167 H. pylori-negative. Among the non-LC patients with peptic ulcers, 9233 were H. pylori-positive and 3188 were H. pylori-negative. On the basis of logistic regression analysis, decompensated LC patients (OR=0.23, P<0.001) and compensated LC patients (OR=0.48, P<0.001) had lower H. pylori infection rates.
CONCLUSION: H. pylori is not the predominant etiology for LC, especially the decompensated type, either with peptic ulcer disease or with recurrent ulcer disease.

Entities:  

Mesh:

Year:  2013        PMID: 23044811     DOI: 10.1097/MEG.0b013e32835a1b26

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  7 in total

Review 1.  Gastrointestinal dysfunction in liver cirrhosis.

Authors:  Evangelos Kalaitzakis
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

Review 2.  Helicobacter pylori-negative, non-steroidal anti-inflammatory drug: negative idiopathic ulcers in Asia.

Authors:  Katsunori Iijima; Takeshi Kanno; Tomoyuki Koike; Tooru Shimosegawa
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

Review 3.  Helicobacter pylori: Effect of coexisting diseases and update on treatment regimens.

Authors:  Shen-Shong Chang; Hsiao-Yun Hu
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-11-06

4.  Association between early Helicobacter pylori eradication and a lower risk of recurrent complicated peptic ulcers in end-stage renal disease patients.

Authors:  Shen-Shong Chang; Hsiao-Yun Hu
Journal:  Medicine (Baltimore)       Date:  2015-01       Impact factor: 1.889

5.  High prevalence of asymptomatic peptic ulcers diagnosed during screening endoscopy in patients with cirrhosis.

Authors:  Theodoros Voulgaris; Dimitrios Karagiannakis; Spyridon Siakavellas; Despina Kalogera; Theodoros Angelopoulos; Elissavet Chloupi; George Karamanolis; George Papatheodoridis; John Vlachogiannakos
Journal:  Ann Gastroenterol       Date:  2019-07-06

6.  Association of Helicobacter Pylori With Development of Peptic Ulcer Disease Among Cirrhotic Patients: An Evidence From Population-Based Study.

Authors:  Tsu Jung Yang; Krithika Dhanasekar; Renu Bhandari; Divya Muraleedharan; Swathy S Chirindoth; Harpreet Kaur; Ruchir Goswami; Prakash Maiyani; Maheshkumar Desai; Dharmeshkumar V Moradiya; Hiteshkumar Devani; Achint A Patel
Journal:  Cureus       Date:  2021-11-06

7.  Helicobacter pylori Eradication within 120 Days Is Associated with Decreased Complicated Recurrent Peptic Ulcers in Peptic Ulcer Bleeding Patients.

Authors:  Shen Shong Chang; Hsiao-Yun Hu
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.